Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01681576 · ClinicalTrials.gov registry record · Phase 2
Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Completed
- Registry status
- Phase 2
- Development phase
- 72
- Enrollment target
NCT01681576 is a Phase 2 study that has completed, run by Novartis Pharmaceuticals. The registered enrollment target is 72 participants.
The verdict
NCT01681576, a Phase 2 study, has completed, sponsored by Novartis Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 72 participants
- Enrollment target
Study Summary
This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.
Interventions
- DRUG Valsartan
- DRUG LCZ696
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 72 participants |
| Start Date | 2012-08 |
| Est. Completion | 2013-10 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01681576
The ClinicalTrials.gov registry entry for NCT01681576 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 72 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Valsartan is the first listed.
NCT01681576 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT01681576 about?
NCT01681576 is a clinical study titled "Assessment of LCZ696 and Valsartan in Asian Patients With Salt-sensitive Hypertension". This study will evaluate the effect of LCZ696 and valsartan on natriuresis, diuresis, and blood pressure in salt-sensitive Asian hypertensive patients.
What is the current status of trial NCT01681576?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 72 participants. The study started on 2012-08. Estimated completion is 2013-10.
What interventions are being tested in trial NCT01681576?
The interventions under investigation include: Valsartan (DRUG), LCZ696 (DRUG).
Who is sponsoring clinical trial NCT01681576?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.